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Abstract: Chronic insomnia disorder, which affects 6–10% of the population, is diagnos
tically characterized by ongoing difficulties with initiating or maintaining sleep occurring at
least three times per week, persisting for at least 3 months, and associated with daytime
impairment. While chronic insomnia is often considered a condition primarily related to
impaired sleep, the disorder can also adversely affect domains of physical and mental health,
quality of life, and daytime function, which highlights the importance of treating the multi
dimensional sleep disorder. Owing to misperceptions about the safety and effectiveness of
treatment options, many individuals with insomnia may not seek professional treatment, and
alternatively use ineffective home remedies or over-the-counter medications to improve
sleep. Some physicians may even believe that insomnia is remediated by simply having
the patient “get more sleep”. Unfortunately, treatment of insomnia is not always that simple.
The disorder’s complex underlying pathophysiology warrants consideration of different
nonpharmacologic and pharmacologic treatment options. Indeed, recent insights gained
from research into the pathophysiology of insomnia have facilitated development of newer
treatment approaches with more efficacious outcomes. This narrative review provides
a summary of the diagnostic criteria and pathophysiology of insomnia and its subtypes.
Further, this review emphasizes new and emerging nonpharmacologic and pharmacologic
treatments for chronic insomnia, including recent enhancements in approaches to cognitive
behavioral therapy for insomnia (CBT-I) and the new dual orexin receptor antagonist
(DORA) pharmacologics. These advances in treatment have expanded the treatment options
and are likely to result in improved outcomes in patients with chronic insomnia.
Keywords: dual orexin receptor antagonists, cognitive behavioral therapy-insomnia,
insomnia subtype, hypnotic
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Insomnia disorder is described by the American Academy of Sleep Medicine
(AASM) International Classification of Sleep Disorders, Third Edition, as having
frequent and persistent difficulty initiating or maintaining sleep that results in general
sleep dissatisfaction despite adequate opportunity for sleep. The sleep complaint is
also accompanied by distress about poor sleep and/or impairment across various
domains of functioning (eg, family, social, vocational, academic).1,2 Insomnia is
classified short-term if it persists less than 3 months and chronic if it persists at
least 3 months and occurs at least three times per week.1,2 Similar essential features of
insomnia are described in the American Psychiatric Association (APA) Diagnostic
Neuropsychiatric Disease and Treatment 2021:17 2549–2566
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and Statistical Manual of Mental Disorders, Fifth Edition
and include dissatisfaction with sleep quantity or quality
with complaints of difficulty initiating or maintaining
sleep.3 The sleep disturbance must also cause clinically
significant distress or impairments in social, occupational,
or other important areas of functioning and may occur
independently or during the course of another mental dis
order or medical condition.3 For many, insomnia becomes
a long-term and persistent condition. A recent longitudinal
study based on annual survey data demonstrated that 37.5%
of participants with insomnia disorder at baseline continued
to report insomnia symptoms through 5 years of follow-up.4
The International Classification of Sleep Disorders,
Third Edition and Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition also describe several sec
ondary insomnias, which arise from co-occurring primary
or causative conditions including mental disorders (eg,
major depressive disorder), medical conditions (eg, pain),
substance use, or another sleep disorder (eg, breathingrelated sleep disorder).1,3 Despite these insomnia subtypes,
it is often difficult to differentiate between them clinically
due to substantial symptom overlap between primary and
secondary insomnia. Additionally, it is often difficult to
assign causation to any single factor or establish the pre
cise nature of the relationship between insomnia and a cooccurring condition.3 Indeed, insomnia frequently persists
despite resolution of other conditions and often requires
independent treatment.5,6 Some studies have shown that
cotreatment of insomnia and co-occurring conditions yield
more rapid improvement of both conditions compared
with independent treatment of only the co-occurring con
dition, supporting the treatment of insomnia as an inde
pendent condition in patients considered to have the
“secondary” condition due to a primary medical or mental
cause.7,8 Other than the different treatments required for
distinctive comorbidities, effective treatments for insomnia
generally are the same across “primary” or “secondary”
insomnia.1,2,9,10 It is important to note, however, that for
some of the more recent insomnia treatments (eg, dual
orexin receptor antagonists [DORAs]), less is known
about their effectiveness in patients with insomnia and
comorbidities as these newer agents are relatively new
and studies of those that have become commercially avail
able have not yet been conducted to evaluate their efficacy
specifically in insomnia patients with co-occurring
disorders.
In addition to short-term and chronic classifications,
insomnia can also be categorized into subtypes
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(phenotypes) based on the timing of the sleep difficulty
occurrence.11–13 The main categories are difficulty falling
asleep (sleep-onset insomnia), difficulty staying asleep
(sleep-maintenance insomnia), early-morning asleep sig
nalingnings coupled with an inability to return to sleep
(terminal insomnia), and combined insomnia (more than
one of these categories).13,14 Additionally, insomnia with
objective short sleep duration (<6 hours by polysomnogra
phy) has also been identified as an important phenotype.15
Identification of a patient’s specific insomnia phenotype
(eg, sleep-onset versus sleep-maintenance insomnia) may
help guide treatment.14 It is critically important to recog
nize the dynamic nature of insomnia, and that the stability
of a patient’s insomnia symptoms may vary over time.13
A 4-month longitudinal study of general practice attenders
found that only 17–51% of the patients reported the same
sleep complaint(s) at follow-up.12 Similarly, in a large,
longitudinal community-based study of individuals with
current or lifetime insomnia, approximately 60% retained
the same insomnia symptom phenotype after 1 year; 40%
had a different phenotype.14 The demonstration in these
studies that many patients have conversion of their insom
nia symptoms12,14 highlights that ongoing assessment is
needed to monitor for potential changes in the presenting
insomnia symptoms.
In addition to impairing sleep, insomnia can cause
adverse consequences across domains of physical and
mental health, quality of life, and daytime function.
Certainly, lack of sleep/insomnia is associated with
increased risk of premature mortality16 and linked to ser
ious somatic and psychiatric conditions, including cardio
vascular and cerebrovascular disease, diabetes,
hypertension, obesity, depression, and post-traumatic
stress disorder.16–24 Further, insomnia may not necessarily
be ameliorated when comorbidities are otherwise success
fully managed. A common example of this is persistent
sleep difficulties in a person with major depressive disor
der despite the substantial relief of mood symptoms with
antidepressant medication.25 Insomnia disorder can also
have direct adverse effects on mood and behavior, includ
ing risk for incident depression and anxiety,26 as well as
a strong link with suicidal ideation.27 Treating insomnia
can prevent depression in many “at-risk” individuals not
depressed at baseline.28
People with chronic insomnia often have more medical
problems than those without insomnia.29,30 In a large-scale
assessment of sleep and health (>9000 elderly individuals),
participants with chronic insomnia symptoms and those
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reporting rarely or never feeling rested upon asleep signa
lingning were more likely to have respiratory symptoms,
physical disabilities, and depressive symptoms; selfreported poorer health; and used more nonprescription
medications than those without sleep symptoms.29
Likewise, a retrospective analysis conducted in
a community-based population found that adults with
insomnia had higher rates of heart disease, high blood
pressure, neurologic disease, breathing problems, urinary
problems, chronic pain, and gastrointestinal problems.30
Moreover, a retrospective analysis found that more indivi
duals with medical problems reported they had symptoms
of chronic insomnia compared to those without medical
problems, suggesting considerable comorbidity between
insomnia and medical disorders.30
The consequences of insomnia extend even further in
that it can also reduce quality of life (QOL), impair
neurocognitive functioning,31 and pose economic and
public health burdens through increased health care uti
lization, sick leave, and decreased work productivity.32,33
An international cross-sectional survey comparing
health-related QOL among sufferers of chronic insomnia
with good sleepers found that people with insomnia
reported significantly reduced health-related QoL as
assessed using the 36-Item Short-Form Health
Survey.34,35 Likewise, in the National Epidemiologic
Survey on Alcohol and Related Conditions-III (2012–
2013) found that the annual loss of quality-adjusted lifeyears associated with insomnia was significantly greater
than other medical conditions assessed, including arthri
tis, depression, and hypertension.36
In industrialized nations, chronic insomnia disorder is
estimated to occur in 5–10% of the general population,
although some studies suggest that the rate is as high as
33% of the adults.2,37 Despite the large percentage,
a relatively low proportion consult a health care provider
about their sleep.38–40 The low consultation rate may be
due to limited knowledge among the general population
about the safety and availability of insomnia treatments
that can be offered by clinicians. Self-treatment with overthe-counter sleep aids, as well as alcohol, is not unusual.41
Owing to this low rate of consultation about insomnia,
health care providers may not consistently recognize and
diagnose the condition,39 which likely contributes to
undertreatment of insomnia.13,39,42
Given the potential negative impact of chronic insom
nia on patients, clinicians’ knowledge of effective treat
ment strategies is important. To provide such a resource
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for clinicians, the authors developed this narrative review
to summarize the pathophysiology of insomnia and new
developments in non-pharmacologic and pharmacologic
interventions.

Pathophysiology of Insomnia
Several models of insomnia etiology and pathophysiology
have been proposed, most of which suggest that both
external stressors as well as internal psychologic factors
have a role.18 For example, the Spielman model of insom
nia, also known as the “Three Factor” or “Three P” model,
comprises three factors: predisposing, precipitating, and
perpetuating.43 Predisposing factors are traits that predis
pose an individual to insomnia such as sleep reactivity,44,45
personality traits including the tendency to worry or rumi
nate, and social factors such as sleep schedule incompat
ibility between bed partners or social pressures leading to
a nonpreferred sleep schedule.45 The combination of pre
disposing factors and precipitating factors (stressors, etc)
can lead to the triggering of insomnia.44 Chronic insomnia
is often maintained by perpetuating factors or behaviors
adopted in an attempt to mitigate insomnia symptoms and
compensate for sleep deficits, such as going to bed earlier
or remaining in bed longer.45 These behaviors lead to the
dysregulation of sleep homeostasis.45 Thus, even after the
elimination or improvement in the initial triggering factor,
insomnia may persist.46
Hyperarousal refers to a state of increased somatic,
cognitive, and cortical activation occurring in the central
and/or peripheral nervous systems, which often includes
both cognitive and emotional processes.47 Physiological
hyperarousal is associated with short sleep duration in
insomnia and activation of both limbs of the stress system
(the hypothalamic-pituitary-adrenal axis and the sympa
thetic system).18 Consistent with the concept of hyperar
ousal being associated with stress, many patients with
insomnia have increased secretion of adrenocorticotropic
hormone and cortisol compared with healthy individuals.46
Although patients with insomnia have overall normal cir
cadian secretory patterns of these hormones, their levels
are elevated during the evening and first half of the night,
which is consistent with the concept of the bedroom envir
onment being a source of stress and activation in people
with insomnia.46,48 Patients with insomnia also have
higher overall mean sleep metabolic rates (as indicated
by overall oxygen use) versus individuals without
insomnia.49 Similarly, in a functional positron emission
tomography study conducted in individuals with and
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without insomnia, patients with insomnia had altered glu
cose metabolism in the brain during sleep and while asleep
signaling compared with individuals without insomnia.50
This altered metabolism may be related to hyperactivation
of arousal mechanisms, which fail to decrease during the
wake-to-sleep transition.50 This physiological hyperarou
sal may be related to worry and rumination. Both worry
and rumination can also lead to emotional arousal and
heightened levels of distress that may activate the stress
system, which can contribute to hyperarousal as well as
the perpetuation of insomnia.51,52 The sleep loss itself may
also exacerbate cognitive hyperarousal at night owing to
increased wakefulness while lying in bed, which may
further exacerbate insomnia and rumination.53
Genetic factors also contribute to the regulation of
sleep-wake traits, including sleep duration and timing of
sleep.47 Current evidence suggests that multiple genes
related to brain functioning, arousal regulation, and sleepwake processes are associated with insomnia.47 The first
studies conducted to identify genes potentially involved in
insomnia examined the role of circadian genes (eg, CLOCK
and the Per genes).47 While the overall genetic heritability
of insomnia is moderate (30–40%),54 only small associa
tions with specific polymorphisms (eg, Timeless, Per2, and
Per3) have been identified, suggesting other factors are
involved.55–58 Indeed, the serotonin transporter-linked
polymorphic region (5-HTTLPR) within the serotonin
transporter (SLC6A4) gene promoter has been implicated
as contributing to poor sleep via stress reactivity
mechanisms.59
Wake/sleep signaling in the brain is driven by two
competing sets of brain circuitry: one set of neurotrans
mitter pathways that promotes sleep and another set that
promotes wakefulness.60 Transitions between sleep and
wake states are dependent on the relative strengths of the
two opposing sets of circuits and the end result has been
described as akin to a flip-flop switch.60 Historically, the
most common approach in the pharmacologic treatment
of insomnia has been to increase the sleep signal, such as
with medications that target the γ-aminobutyric acid
(GABA)-A receptor. However, this may not be the best
approach physiologically if the insomnia disorder is due
to excessive wake signaling occurring at the time when
the individual is expected to fall asleep and remain
asleep. Decreasing the excessive wake signal has
recently become a viable option for medication treatment
now that orexin has been identified as a key central
promotor of wakefulness.
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The orexin neuropeptide signaling system is
involved in several physiological functions, particularly
sleep and arousal.61 It is one of the primary systems
that maintains wakefulness throughout the day and is
involved with the regulation of rapid eye movement
(REM) sleep.61,62 Two neuropeptides, orexin-A (OXA) and orexin-B (OX-B), both derived from the com
mon precursor prepro-orexin, activate two postsynapti
cally localized G protein–coupled receptors, orexin
receptor type 1 (OX1R) and orexin receptor type 2
(OX2R).61 OX1R predominantly interacts with OX-A,
whereas OX2R interacts with OX-A and OX-B with
similarly high affinity.63 Activation of OX1R and
OX2R suppresses the onset of REM sleep and activa
tion of OX2R suppresses non-REM sleep.64 If orexin
binding to either of its receptors causes arousal (wake
fulness), then a substance that acts as an antagonist of
OX1R and/or OX2R for an extended period of time can
promote sleep by inhibiting the wake-promotion asso
ciated with the orexin signaling pathway.65,66

Nonpharmacologic Treatments for
Chronic Insomnia
As regards behavioral and psychological treatments for
chronic insomnia, clinical practice guidelines from the
AASM and the American College of Physicians (ACP)
both indicate that standard-of-care should be to at least
provide cognitive behavioral therapies for insomnia (CBTI) as first-line nonpharmacologic treatment.9,67 Indeed, CBTI is the only nonpharmacologic treatment for chronic insom
nia that has received a strong recommendation for use by the
AASM.9 This is likely due in part by the numerous metaanalyses demonstrating robust clinical improvements across
numerous sleep-related outcomes using individual, group,
internet-based, and self-help CBT-I.68
Other nonpharmacologic treatments for the treat
ment of chronic insomnia have been described in
AASM guidelines. Brief therapies for insomnia, stimu
lus control, sleep restriction therapy, and relaxation
therapy, and sleep hygiene (Table 1) are all included
as potential treatment options.9 However, guidelines
acknowledge that usefulness as a treatment for chronic
insomnia is often based on a small body of low-quality
evidence.9 Further, their uses (except for sleep
hygiene) are mostly indicated as single-component
therapy.
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Table 1 Selected Elements of Good Sleep Hygiene155,156
Element
● Keeping a regular sleep/wake schedule
● Reducing bedroom noise
● Blocking out light
● Removing electronic devices from the bedroom
● Avoiding daytime napping
● Avoiding alcohol, nicotine, and caffeine before sleeping
● Avoiding eating dinner late
● Regular exercise
● Management of stress

CBT-I
CBT-I includes a combination of behavioral interventions:
stimulus control therapy to pair the bed with sleep, sleep
restriction/compression to increase sleep pressure, relaxa
tion training to reduce hyperarousal, specific cognitive
interventions aimed at changing patients’ beliefs and atti
tudes about sleep, and sleep hygiene education.69,70
Cognitive strategies (such as cognitive restructuring to
identify and address dysfunctional beliefs and unrealistic
expectations that can perpetuate insomnia) are used as part
of CBT-I to break a cycle that can lead to, maintain, or
worsen insomnia.71 Although cognitive therapy and beha
vioral therapy alone are effective, patients derive the most
benefit when all components of CBT-I are combined with
an eight-week course of treatment.69,72 It should be noted
that CBT-I may be contraindicated in some patients. Sleep
loss through sleep restriction in CBT-I may exacerbate
comorbidities including seizure disorders, severe obstruc
tive sleep disorder, untreated bipolar disorder, in indivi
duals who are actively suicidal, or in patients with severe
parasomnias.73–75
However, not all patients with insomnia disorder may
receive sufficient benefit from CBT-I.2,10 Indeed, only
approximately 30–40% of the patients undergoing CBT-I
reach remission.76–79 This may be due to the time commit
ments, the work involved to change sleep habits and
schedules, and highly engrained maladaptive beliefs
about sleep.2,80 Also, an important consideration for
CBT-I is that some behavioral treatments may be more
appropriate for specific insomnia phenotypes.14 For exam
ple, relaxation may be more useful for sleep onset insom
nia, whereas sleep restriction, which increases the pressure
for sleep so that sleep inevitably occurs without attention,
intention, or effort, may benefit both sleep onset and sleep
maintenance insomnia.14,81 At times, the typical CBT-I
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approach may have limited usefulness because there are
too few sessions to address the engrained ways of thinking
about and interpreting one’s own sleep. This can result in
the CBT-I not having a powerful enough effect on the
cognitive arousal that occurs at night to provide full
remission.
As a caveat, some individuals may have persistent
maladaptive beliefs. In an assessment of the effects of
CBT-I on sleep-related dysfunctional beliefs, a significant
correlation was found between the Athens Insomnia Scale
and the Dysfunctional Beliefs and Attitudes About Sleep
Scale at baseline and improvements occurred on both
scales following CBT-I.82 However, the decrease in dys
functional beliefs and attitudes about sleep was not related
to improvements in or decreased severity of insomnia.82
Several barriers prevent CBT-I from being more widely
used in clinical practice.80 Not all patients are able to gain
access to CBT-I because of a lack of availability of providers or
cost constraints.2,80 In addition, CBT-I requires patients to
make a considerable time commitment that they may be unable
or unwilling to do. CBT-I also requires a substantial time
investment of trained clinicians, which means demand for
CBT-I providers often exceeds supply.80,83 Both health care
practitioners and patients may lack sufficient knowledge about
CBT-I and its effectiveness.80 Many health care practitioners
do not refer their patients for treatment with CBT-I alone,
despite CBT-I being a first-line treatment.84 A 2015 survey of
physicians found that a majority considered medications and
other treatment options to be more effective than CBT-I
alone.84 Thus, more clinician education about CBT-I is neces
sary and new approaches to its delivery are needed.84
A way to increase access to CBT-I is through “stepped
care,” which is a sequential approach to care management
that manages high patient volume via low-intensity treat
ments initially and progressively moves to more intense
treatment based on assessed need.85 The initial therapeutic
approach should be the least restrictive therapy, readily
accessible, the lowest cost, and least inconvenient for
patients.85 For insomnia treatment, the entry-level treatment
would be self-administered CBT-I with more specialized
types of CBT-I, such as manualized, small-group CBT-I
delivered by nurses, and eventually sleep specialists,
including psychologists, at higher levels.85
Providing CBT-I via the internet (digital CBT-I) is
another possible solution to reduce the time investment
and increase accessibility.83 In a randomized controlled
trial comparing six guided online CBT-I sessions to six
face-to-face CBT-I sessions or wait-listing potential
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participants meeting the Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition criteria for insomnia,
both face-to-face and online interventions had significantly
larger treatment effects than the wait-list group.83 The
face-to-face treatment yielded a statistically greater treat
ment effect than the online sessions; however, some
improvements were also seen with online CBT-I, suggest
ing that digital delivery of CBT-I may provide an alter
native and/or companion to face-to-face treatment.83 In
addition, in a recent meta-analysis of randomized clinical
trials comparing digital CBT-I to controls, digital CBT-I
significantly reduced insomnia severity and was noninfer
ior to face-to-face delivery.86 In fact, digital CBT-I not
only improves insomnia but it also has robust and longlasting effects on improving and preventing depression in
patients with insomnia disorder.28
Another new technology useful for facilitating CBT-I is
the use of a smartphone application (app) such as CBT-I
Coach. CBT-I Coach is a patient-facing app from the US
Department of Veterans Affairs, Stanford University’s
School of Medicine, and the US Department of Defense
National Center for Telehealth and Technology designed to
enhance CBT-I.87 CBT-I Coach is intended for use by
patients undergoing CBT-I with a health care professional
to act as an educational resource to support, but not
replace, the clinician-delivered CBT-I.87 The app provides
automated sleep diary calculations, sleep education, tools
to practice CBT-I skills, and reminders to complete sleep
diaries and follow recommendations for time in bed.87
These reminders have the potential to reduce treatment
dropout and address common adherence issues and, there
fore, may improve insomnia outcomes.87 Surveys of US
Department of Veterans Affairs physicians trained in deli
vering CBT-I regarding their perceptions of CBT-I Coach
2 years after its launch demonstrated that almost 60% of
the clinicians were using the app with their patients and
had a favorable view of its utility in improving CBT-I
outcomes.87
A newer approach to CBT-I therapy itself is to employ
a combination of mindfulness-based stress reduction with
CBT-I.88 This combination approach, which is sometimes
called mindfulness-based therapy for insomnia (MBTI),89
results in statistically significant and clinically meaningful
improvements in multiple nighttime symptoms of insom
nia. In addition, significant reductions in presleep arousal,
sleep effort, and dysfunctional sleep-related cognitions
were observed.88 This may be due, in part, to the fact
that MBTI was designed to address rumination.52 In an
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assessment of the long-term effects of the MBTI
approach, the benefits of this combined approach on
insomnia and symptom severity were generally main
tained during the 12-month follow-up.90 Use of one or
more of these newer approaches to CBT-I, such as digital
CBT-I and/or MBTI, may be critical to increase the
response of patients to nonpharmacologic treatments for
insomnia.
Other new methods of behavioral treatment include
CBT-I for specific populations. For example, owing to
hormonal, anatomic, and physiological changes, pregnant
women tend to experience sleep disturbances and insom
nia more frequently than the general population.91 Since
patients and prescribers are likely to have concerns about
the use of sleep medication in women who are pregnant or
breastfeeding, CBT-I may be a more appropriate and pre
ferred intervention for insomnia during pregnancy and the
postpartum period.91,92 In a randomized, unmasked, con
trolled trial comparing CBT-I to control insomnia therapy
(modified pseudodesensitization therapy for insomnia) in
women with insomnia disorder between 18 and 32 weeks
of pregnancy, CBT-I was associated with significantly
faster remission of insomnia. In addition, significantly
greater improvements in insomnia severity, total wake
time, and Edinburgh Postnatal Depression Scale scores
versus control therapy (p<0.01 for all) were also
observed.93 More women treated with CBT-I attained
remission of insomnia than with control therapy with
a favorable effect size.93,94
Similarly, the hormonal fluctuations associated with
menopause mean that postmenopausal women also experi
ence insomnia at higher rates than the general
population.91 In a clinical trial comparing CBT-I to sleep
restriction therapy and sleep hygiene education to treat
insomnia in postmenopausal women, CBT-I was asso
ciated with greater improvement in Insomnia Severity
Index scores, increased improvement in sleep duration,
and greater remission rates than sleep restriction therapy
or sleep hygiene education.95 In addition, both CBT-I and
sleep restriction therapy improved fatigue, energy, sleepi
ness, and work function.96 Whereas sleep restriction ther
apy and sleep hygiene education improved resilience to
physical problems, CBT-I was associated with substantial
improvements in emotional well-being and resilience to
both physical and emotional problems.96 CBT-I also
reduced depressive symptoms, dysfunctional beliefs
about sleep, and presleep somatic hyperarousal in
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postmenopausal women more than sleep restriction ther
apy and sleep hygiene education.97

Forehead Temperature Cooling
An alternative nonpharmacologic approach to treating
insomnia is to reduce the increased activity and frontal
cerebral metabolism that occurs during hyperarousal in
patients with insomnia by application of a cooling stimulus
to the scalp.98 Application of a novel forehead temperature
regulating device that can be adjusted to deliver frontal
cerebral thermal therapy ranging from 14°C to 16°C (57–
61°F) produced improvements in latency to persistent
sleep, latency to stage 1 non-REM sleep, latency to stage
2 non-REM sleep, and an increase in the number of
minutes of sleep during the first hour of sleep with
a trend to reduce latency to stage 3 non-REM sleep.
These improvements were observed in men and women
with primary insomnia (defined per Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition)
without major syndromal mood, anxiety, psychotic, sub
stance use or current sleep disorders other than insomnia.98
Similar improvements in insomnia, as well as improve
ments in anxiety and depressive symptoms, were observed
when a forehead cooling device was studied in veterans
with chronic insomnia disorder and comorbid medical and
psychiatric conditions.99 These results suggest that this
device could be useful for patients who prefer nonpharma
cologic methods of treating insomnia, but are unable to use
CBT-I, or as adjunctive therapy for other treatments
although the long-term efficacy and safety of this approach
needs to be evaluated.98,99

Pharmacologic Treatments for Chronic
Insomnia
Treatment Guidelines and Recommendations for
Pharmacologic Treatments
Not all patients with chronic insomnia disorder benefit
from CBT-I alone or have access to this modality.2
Treatment guidelines from both the APA and the ACP
recommend health care practitioners use a shared decisionmaking approach with patients when considering whether
to use or add pharmacologic therapy.2,67 This approach
should include a discussion of the benefits, risks, and
costs associated with the use of medications.67
The pharmacologic therapies listed in the treatment
guidelines from the ACP include those medications
approved by the US Food and Drug Administration
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(FDA) for treatment of insomnia, such as benzodiazepines
(BZDs) and the non-BZD hypnotic “Z-drugs”, the DORAs
suvorexant, the melatonin receptor agonist ramelteon, and
the first-generation histamine antagonist doxepin, as well
as off-label use of other agents.67 However, these guide
lines note that there was insufficient evidence to determine
the efficacy or the benefit:risk ratio of many of these
therapies, and therefore the guidelines do not make any
specific recommendations for any single medication.67
Similarly, the AASM makes suggestions about
whether specific pharmacologic therapies should be
used for the treatment of sleep onset and/or sleep main
tenance insomnia.2 Several medications including differ
ent BZD receptor agonists and BZDs are recommended
for treating both insomnia subtypes.2 Therapies recom
mended specifically for use in sleep onset insomnia
include the BZD receptor agonist zaleplon, the BZD
triazolam, and the melatonin agonist ramelteon, whereas
recommended therapies for sleep maintenance insomnia
include suvorexant and doxepin.2 However, trazodone,
the anticonvulsant tiagabine, and over-the-counter medi
cations
such
as
diphenhydramine,
melatonin,
L-tryptophan, or valerian are not recommended for treat
ing either type of insomnia.2 All of the specific recom
mendations by the AASM are classified as “weak”
because they are based on the degree of confidence in
the availability of efficacy data, quality of efficacy data,
and other considerations, including potential risks and
patient preferences.2 The weak classification of these
recommendations should not be misinterpreted as mean
ing that sleep-promoting medications are not efficacious
or indicated for insomnia treatment, just that the existing
data limit the degree of confidence in these
recommendations.2
It is important to note that the most recent ACP and
AASM guidelines predate the approval of the DORA
lemborexant, which was approved in the United States in
December 2019, in Japan in January 2020, and in Canada
in November 2020.100,101
In addition, the 2019 American Geriatrics Society
Beers Criteria for Potentially Inappropriate Medication
Use in Older Adults indicate that older adults should
avoid BZDs and non-BZD hypnotic “Z-drugs” because
of increased sensitivity to these medications and the
increased risk of cognitive impairment, delirium, falls,
fractures, and motor vehicle accidents.102 Older patients
should also avoid doxepin doses >6 mg owing to the
potential for orthostatic hypotension.102
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Pharmacologic Agents Used for Treating Insomnia
Historically, pharmacologic agents such as opioids, herbal
preparations, barbiturates, alcohol, and pain medications
have been used to treat insomnia or to manage sleep
disturbances.2,38,39 Whereas alcohol can act as a sedative,
intake of large amounts of alcohol prior to sleep can cause
changes in sleep architecture and disrupted, poor-quality
sleep, which can contribute to insomnia.103 Many of the
other early therapies were effective, but they were asso
ciated with next-day residual effects, development of phy
siological tolerance, and dependence, adverse effects
following long-term use, withdrawal effects, and concerns
regarding abuse and misuse.2,13 In addition, health care
practitioners often cite concerns about safety and depen
dency as key reasons why they hesitate to treat insomnia
with medications, particularly BZDs and the non-BZD
hypnotics.2

Hypnotics
Clinical trials of hypnotic medications often select partici
pants based on their specific insomnia phenotypes, which
could affect the indications and labeling of these agents
based on whether they affect sleep onset difficulties, sleep
maintenance problems, or both.14 The AASM treatment
guidelines for insomnia also make similar distinctions
regarding the use of pharmacologic agents.2,14 For exam
ple, the BZD receptor agonists zolpidem and zaleplon are
often prescribed for patients with sleep onset insomnia
because they are fast acting and have relatively short halflives.13,104 In addition, unlike BZDs (which reduce stage 3
and 4 sleep), non-BZD receptor agonists do not consis
tently alter sleep architecture, although high doses may
reduce REM sleep.105 However, the short half-life of
these agents may not be as effective for sleep maintenance
problems,13 although zolpidem is also available as an
extended-release formulation, which has demonstrated
efficacy on sleep onset and sleep maintenance
outcomes.106
GABA is the main inhibitory transmitter in the mam
malian brain and works through GABA-A and GABA-B
receptors.107 BZDs and non-BZD hypnotics act as positive
allosteric modulators on GABA-A receptors, which are
widespread throughout the brain, to enhance the action of
GABA and cause sedation by prolonging the duration of
inhibitory postsynaptic currents.107 This increase in
GABA transmission has an inhibitory effect on norepi
nephrine transmission through wake-promoting pathways,
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which causes sedation and inhibition of wake-promoting
regions of the brain, thereby promoting sleep.108
As discussed, stability of a patient’s insomnia symp
toms may vary over time.12–14 Whereas follow-up and reassessment of the presenting pattern of insomnia should be
conducted regularly,104 using agents with effects on both
sleep initiation and maintenance could address the lack of
stability in these temporal insomnia phenotypes. This
could also minimize the need for patients to switch med
ications if their symptoms change over time.
An optimal pharmacologic treatment for insomnia
should not only improve sleep maintenance, sleep onset,
sleep quality, and daytime functioning, but also be safe and
effective for long-term use without next-day residual effects
or symptoms of tolerance, rebound, or dependence.13 The
treatment should also normalize sleep architecture by redu
cing sleep onset latency (SOL), wake after sleep onset
(WASO), awakenings, arousals, and frequency and duration
of wake episodes, as well as maintaining normal sleep stage
amounts and distribution. Some of the medication therapies
mentioned in treatment guidelines may have limited effi
cacy in treating all phenotypes of insomnia and/or they may
be limited by safety and tolerability concerns. For example,
whereas specific BZDs are indicated for treating patients
with sleep onset insomnia, sleep maintenance insomnia, or
both sleep onset and sleep maintenance insomnia, this class
of agents can cause next-day sedation and cognitive impair
ment, and is associated with an increased risk for abuse and
dependence.13 In addition, in 2019, the FDA added boxed
warnings about the possibility of complex sleep behaviors,
such as sleepwalking and sleep driving, to prescribing
information and patient medication guides for eszopiclone,
zaleplon, and zolpidem.109 Thus, formation of
a pharmacologic treatment plan is directed by several fac
tors including perhaps most prominently, symptom pattern
(eg, difficulty with sleep onset vs sleep maintenance), as
well as treatment efficacy (eg, reduced SOL vs WASO) and
side effects.10

Dual Orexin Receptor Antagonists:
A New Class of Pharmacologic Treatment
for Insomnia
The DORAs block OX1R and OX2R and promote sleep
through a decrease in arousal signaling, which, as has been
noted, is a different therapeutic approach for
insomnia.65,66,110,111 Several DORAs have been evaluated
for the treatment of insomnia preclinically and in clinical

Neuropsychiatric Disease and Treatment 2021:17

Dovepress

Rosenberg et al

trials, with two DORAs currently approved for use
(Table 2).66,100,101,112 Of note, orexin receptor antagonists do
not adversely affect sleep architecture.113,114 They have been
found to shorten REM latency and increase TST, mainly by
increasing the time spent in REM sleep.113–115 However the
percentage of TST spent in non-REM sleep is left unchanged
or possibly lowered.113–115 They do not appear to be asso
ciated with tolerance, withdrawal, or rebound insomnia if
abruptly discontinued.116–118 Importantly, the mechanism of
action of DORAs suggests that daytime sleepiness would be
further exacerbated in patients with narcolepsy (as they
already have impaired orexin-mediated wake signaling).119–
121
Accordingly, DORAs are contraindicated in these patients.
After its initial approval in Japan,112 suvorexant was the
first DORA to receive approval in the United States, where it
is indicated for the treatment of insomnia characterized by
difficulties with sleep onset and/or sleep maintenance.122
Suvorexant has received subsequent approvals in Australia
and Canada.123,124 The efficacy and safety of suvorexant were
evaluated in two randomized double-blind, placebocontrolled, parallel-group Phase 3 clinical trials conducted
for 3 months, as well as in one randomized, placebocontrolled, parallel-group phase 3 clinical trial conducted for
1 year.116,117 In both the 3-month trials, the higher dose,
suvorexant 40/30 mg (40 mg in patients 18–64 years of age
and 30 mg in patients ≥65 years of age; not approved),
demonstrated superiority versus placebo in improving patient-

reported subjective total sleep time (sTST), subjective time to
sleep onset (sTSO), subjective WASO (sWASO) and poly
somnography (PSG)-measured wakefulness after persistent
sleep onset when assessed at 1 week, 1 month, and 3
months.116 Suvorexant 40/30 mg also demonstrated super
iority versus placebo in improving PSG-based latency to
onset of persistent sleep (LPS) in both trials when assessed
at 1 week and 1 month, but in only one trial when assessed at
3 months.116 The lower dose (suvorexant 20/15 mg; 20 mg in
patients 18–64 years of age and 15 mg in patients ≥65 years
of age) was superior to placebo on sTST and wakefulness
after persistent sleep onset at all study time points, and on
sTSO and LPS for most time points.116 In the 1-year trial,
suvorexant 40/30 mg significantly improved sTST and sTSO
over the first month of treatment versus placebo.117 However,
long-term data on approved doses of suvorexant are not
available. Significant improvements with suvorexant 40/
30 mg versus placebo were also observed for sWASO at 1
month, and for sTST, sTSO, and sWASO at 12 months.117
Additionally, in a four-week, double-blind, placebo-controlled
study in 285 patients with mild to moderate Alzheimer’s
disease, suvorexant (10–20 mg) improved TST as determined
by PSG.125
Suvorexant was well tolerated in the phase 3 clinical
trials with low rates of patients discontinuing because of
adverse events or experiencing serious adverse
events.116,117 Incidences of rebound insomnia, next-

Table 2 Orexin Receptor Antagonists Approved or in Development for Treatment of Insomnia Disorder
Name

Development

Doses

Half-Life

Use in Special Populations

5 mg,

Terminal half-life: approximately 15 hours

● Not recommended in patients with

10 mg,
15 mg,

(range, 10–22 hours)

severe hepatic impairment
● Safety and effectiveness have not been

Status
Suvorexant

Approved

(BELSOMRA®)122

established in pediatric patients

20 mg
Lemborexant

Approved

5 mg, 10 mg

(DAYVIGO®)131

Daridorexant157

Effective half-life for lemborexant 5 mg: 17
hours; effective half-life for lemborexant 10 mg:

Filing in
preparation

10 mg,
25 mg,

● Not recommended in patients with
severe hepatic impairment

19 hours

● Safety and effectiveness have not been
established in pediatric patients

Elimination half-life: 5.6–8.5 hours158

● Prescribing information not available

Half-life: 2–3 hours149

● Under development for use in patients

50 mg145,146
Seltorexant149

Phase 3

20 mg

with major depressive disorder and
insomnia
● Prescribing information not available
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morning effects, and withdrawal signs or symptoms were
low in the clinical trials.116,117 Similar results were
reported in a pooled analysis of the 3-month data from
the three phase 3 clinical trials.126 Overall benefit-to-risk
ratio for suvorexant treatment is favorable, as measured by
number needed to treat, number needed to harm, and like
lihood to be helped or harmed.127
Suvorexant was also assessed in patients with mild to
moderate obstructive sleep apnea (OSA).128 This is of
interest because some current insomnia medications, such
as BZDs, are associated with respiratory depression, which
raises safety concerns, particularly in individuals with
compromised respiratory function, such as those with
OSA. In this randomized, double-blind, placebocontrolled, crossover study, suvorexant 40 mg (twice the
20-mg maximum approved dose) did not appear to affect
respiratory safety during sleep.128
In two clinical studies evaluating performance of nextmorning driving by using a 1-hour standardized highway
driving test in normal traffic conducted 9 hours after dos
ing in healthy volunteers 23–64 or 65–80 years of age, no
clinically meaningful residual effects of suvorexant on
driving performance were found versus placebo.129,130
However, the authors noted that some individuals experi
enced somnolence and prematurely stopped their driving
tests.129,130 Because of concerns related to sleep paralysis,
hypnagogic hallucinations, cataplexy, and suicidal idea
tion, the FDA only approved lower doses of suvorexant
(5, 10, 15, or 20 mg).112,122 Suvorexant is a schedule IV
controlled substance.
In 2019, lemborexant became the second DORA to
receive approval in the United States for the treatment of
insomnia characterized by difficulties with sleep onset and/or
sleep maintenance in adults.131 Similar to suvorexant, lem
borexant is a schedule IV controlled substance. Lemborexant
is also approved in multiple countries, including Japan and
Canada, for the treatment of insomnia.101 In a Phase 2, multi
center, randomized, double-blind, placebo-controlled,
Bayesian, adaptive, parallel-group study of lemborexant (1,
2.5, 5, 10, 15, or 25 mg) for 15 nights, patients (≥18 years of
age) receiving lemborexant at doses ≥5 mg had significantly
greater improvements in sleep efficiency, subjective sleep
efficiency, LPS, and subjective SOL versus placebo.132 In
a randomized, double-blind, parallel-group, placebocontrolled and active-comparator, phase 3 study in females
(≥55 years of age) and males (≥65 years of age) with insom
nia disorder, lemborexant (5 mg or 10 mg) demonstrated
statistically significantly greater improvements on objective
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(PSG-based) measures of sleep onset and sleep maintenance
compared with placebo and with zolpidem tartrate extended
release (6.25 mg) as assessed at 1 month.118 Additionally,
changes from baseline in subjective (sleep diary–based) SOL
were greater and statistically significant with lemborexant
compared with placebo and with zolpidem as assessed at
the end of 1 month.118 Similarly, in a 12-month, randomized,
double-blind, parallel-group, phase 3 study, which was pla
cebo-controlled for the first 6 months, patients (≥18 years of
age) treated with lemborexant (5 mg or 10 mg) had signifi
cantly greater decreases from baseline in the primary end
point of subjective SOL compared with placebo-treated
patients as assessed at the end of 6 months.133 Lemborexant
also demonstrated significant benefit on sWASO, subjective
sleep efficiency, sTST, and quality of sleep compared with
placebo at the end of the 6-month placebo-controlled
period.133 Taken together, these results indicated lemborex
ant exhibits efficacy that is sustained long term.
In both phase 3 clinical trials of lemborexant, the rate of
serious treatment-emergent adverse events (TEAEs) was
low and no deaths occurred; lemborexant was well toler
ated, with most TEAEs rated as mild or moderate in
severity.118,133 Overall, the most prominent adverse event
was somnolence. Similarly, in an analysis of the pharmaco
kinetic, pharmacodynamic, and safety data from three dou
ble-blind, placebo-controlled Phase 1 studies, lemborexant
was well tolerated with no evidence of clinically relevant
next-morning residual sleepiness.134 Overall benefit-to-risk
ratio for lemborexant treatment is favorable, as measured by
number needed to treat, number needed to harm, and like
lihood to be helped or harmed.135
Lemborexant was assessed in otherwise healthy adult and
elderly participants with mild OSA.136 In this phase 1, ran
domized, double-blind, placebo-controlled, two-period
crossover study, there were no significant differences on
measures of respiratory safety including the apnea–hypopnea
index and peripheral oxygen saturation for lemborexant
10 mg versus placebo.136
In an analysis of nine clinical studies conducted during
the clinical development program of lemborexant, which
included assessments of next-morning or across-the-day
residual medication effects, lemborexant did not nega
tively impact next-day functioning in healthy individuals
or patients with insomnia.137 Lemborexant treatment was
associated with significantly greater alertness for up to 6
months versus placebo as determined by next-morning
sleep diary ratings.137 In addition, whereas zolpidem dif
fered from placebo on multiple measures of the Cognitive

Neuropsychiatric Disease and Treatment 2021:17

Dovepress

Performance Assessment Battery, power of attention was
the only measure that found significantly decreased per
formance with lemborexant compared with placebo, and
only in one of two studies.137 Similarly, lemborexant treat
ment was also not associated with statistically significant
or clinically meaningful next-day impairment in
a randomized, double-blind, double-dummy, placebo- and
active-controlled, four-period, incomplete crossover study
conducted in healthy volunteers to determine effects on
driving performance during a standardized highway driv
ing test in normal traffic.138 However, while there were no
stopped drives during the lemborexant conditions, driving
ability was impaired in 2 of the 32 participants receiving
lemborexant 10 mg, and the product label recommends
that patients who take the 10-mg dose should be advised
about the possibility of next-morning driving impairment
due to individual variation in lemborexant sensitivity; of
note, the recommended starting dose of lemborexant is
5 mg.139 The effects of lemborexant, zolpidem, and pla
cebo on auditory awakening threshold and postural stabi
lity in the middle of the night and upon morning
awakening were assessed in healthy females (≥55 years
of age) and males (≥65 years of age).140 Neither lembor
exant nor zolpidem impaired the ability of participants to
awaken to auditory signals in the middle of the night (4
hours post-dose).140 While both lemborexant and zolpidem
induced significantly more postural instability than pla
cebo in the middle of the night (4 hours post-dose), lem
borexant was associated with significantly less postural
instability than zolpidem.140 In the morning (8 hours postdose), postural instability was observed with zolpidem
compared with placebo, but not for lemborexant compared
with
placebo.140
An
open-label
pilot
study
(NCT04009577, E2006-A001-312) has been carried out
to evaluate prespecified dosing approaches for direct tran
sition from zolpidem to lemborexant.141,142 The primary
endpoint of the study, which was recently completed, is
the proportion of patients with insomnia who successfully
transition from intermittent or frequent zolpidem use to
lemborexant 5 mg or 10 mg after 2 weeks of treatment.142
Following the 2-week titration period, 43 out of 53 sub
jects (81.1%) transitioned to lemborexant.
Daridorexant is a DORA that is in development for the
treatment of insomnia; the New Drug Application was
submitted in January 2021. Recently, results from two
phase 2 trials evaluating the efficacy and safety of daridor
exant were published.143,144 One trial was conducted to
evaluate the dose–response relationship of daily
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daridorexant (5, 10, 25, or 50 mg) for 30 days compared
with oral placebo or 10 mg zolpidem in adults (≤64 years
of age) with insomnia disorder.143 Daridorexant induced
a dose-dependent reduction in WASO and subjective
latency to sleep onset with no clinically relevant treatmentrelated serious adverse events and a low rate of disconti
nuation due to adverse events.143 The second trial was
conducted to assess the dose-response of daridorexant (5,
10, 25, and 50 mg) versus placebo in elderly patients with
insomnia.144 Daridorexant-treated patients had statistically
significant, dose-dependent improvements in WASO and
LPS, with similar rates of TEAEs as those patients treated
with placebo.144
The phase 2 trials supported continued development of
daridorexant to phase 3. Positive topline results of the first
pivotal trial, which was conducted to evaluate daridorexant
25 and 50 mg in adult and elderly patients with insomnia,
were announced in April 2020.145 Daridorexant treatment
improved both objective and subjective sleep parameters
and daytime performance over 3 months without evidence
of residual effects, rebound insomnia, or withdrawal
symptoms after discontinuation.145 In July 2020, topline
results from the second phase 3 study, which examined
daridorexant 10 and 25 mg in adult and elderly patients
with insomnia were announced.146 These results were in
agreement with the previous findings and demonstrated
improvements on objective and subjective sleep measures
(sleep onset, sleep maintenance, and sTST) with daridor
exant treatment. Additionally, positive effects on daytime
functioning were observed, with no reports of morning
sleepiness or evidence of rebound or withdrawal
symptoms.146
Almorexant was the first DORA to undergo phase 3
clinical evaluation, but was ultimately discontinued
because of safety findings of abnormally elevated liver
enzymes.66 Other DORAs that had been in clinical devel
opment, SB-649868 and filorexant (MK-6096), completed
phase 2 trials but have since been discontinued.147,148
Seltorexant (JNJ-42847922) is an OX2R antagonist cur
rently in phase 3 clinical development for the treatment of
insomnia and major depressive disorder.149 A phase 2b
active- and placebo-controlled study in adult and elderly
subjects with insomnia disorder found that seltorexant at 5,
10 and 20 mg significantly improved LPS versus
placebo.150 Greater improvement in LPS was also seen
with seltorexant 20 mg compared with zolpidem.150
Additionally, seltorexant improved LPS and TST, and SE
compared with placebo in an exploratory crossover study
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in subjects with antidepressant-treated major depressive
disorder and who have persistent insomnia.151

Practical Advice for Clinicians Treating Patients with
Pharmacologic Therapies
Abrupt changes in treatment with older-generation hypno
tics can lead to rebound insomnia with worsened sleep.152
This is of practical concern because a common scenario is
that of a person with chronic insomnia whose medication
treatment has ceased to be effective because of the devel
opment of physiological tolerance. A new medication
(such as an orexin receptor antagonist) may be prescribed,
but the new intervention may fail if the old hypnotic is
abruptly discontinued because there is no cross-tolerance
between the older medications (such as BZD and nonBZD hypnotics) and orexin receptor antagonists. The
patient may misinterpret this failure as due to inefficacy
of the new therapy rather than the result of abrupt discon
tinuation of the prior medication. A gradual tapering off of
the old hypnotic may help to avoid rebound insomnia,
particularly when the older agent was taken every night
for months or years.152 If patients choose to switch med
ications, health care practitioners should discuss how to
manage this change. A practical approach to managing
changes in insomnia medication includes providing
patients written information about medication discontinua
tion, including a discussion of change in the subjective
experience they may have with the new medication, using
stepped care with a tailored approach to the amount of
intervention, and adding CBT-I or behavioral therapies,
which may help improve the transition during discontinua
tion of a hypnotic therapy.152,153 Additional research is
needed to optimize the process of changing therapies,
especially when patients are switching classes of pharma
cologic treatments.
Because benzodiazepines can depress respiratory drive,
they are generally avoided as hypnotics in patients with
OSA. Although the safety of orexin-receptor antagonists
has been established in patients with mild-moderate
OSA,128,136,154 further studies characterizing the use of
orexin receptor antagonists in insomnia disorder in people
with more severe forms of OSA would also help better
inform clinical practice.
In conclusion, several advances in the nonpharmacologic
and pharmacologic treatment options for chronic insomnia
have occurred recently. The newest delivery enhancements
for CBT-I, such as the stepped-care approach, digital deliv
ery of CBT-I, and the inclusion of mindfulness-based stress

2560

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/NDT.S297504

DovePress

reduction as well as the novel approach of forehead cooling,
may provide patients with insomnia greater access to and
efficacy with nonpharmacologic interventions. In addition,
the availability of the new DORA medication class means
that more pharmacologic options are available for patients.
These new therapies may improve sleep outcomes with
fewer TEAEs and less risk of next-morning residual sleepi
ness or impairments. Additional studies are needed to eval
uate the efficacy of combining newly available
pharmacologic treatments, such as DORAs, with nonphar
macologic treatments. If patients choose to change classes of
therapies from the older pharmacological approaches, health
care practitioners need to educate patients to help them
manage the transition and avoid rebound insomnia, and
thus improve patient satisfaction with their insomnia therapy.
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